应用因特网对SARS病毒M蛋白B细胞抗原表位的预测

目的：预测SARS冠状病毒M蛋白的B细胞表位。方法：采用EMBOSS软件结合Hopp＆woods亲水性参数、Janin可及性参数、极性参数、柔韧性参数及二级结构方案对SARS冠状病毒M蛋白的B细胞表位进行了预测，并用吴玉章等已建立的B细胞表位预测方法进行评述。结果：SARS冠状病毒M蛋白B细胞识别的表位可能位于第3～13和153～166位氮基酸等区域内或附近，这2个被预测的表位均含有β—转角和无规卷曲结构。结论：该研究对应用合成肽抗原进行SARS早期诊断研究及相关抗体的制备具有重要指导意义。     

缬沙坦与苯那普利拉对SHR肾小球系膜细胞的保护作用

目的：观察ARB－valsartan及ACEI－benazeprilat能否抑制由AngⅡ、PDGF引起的SHR肾小球系膜细胞的增殖与肥大。且比较单用时作用孰强孰弱，联合应用后有无协同效应。方法；采用经典SHR系膜细胞培养技术，细胞中加入各种因子和（或）药物，以^3H-leucine或^3H-thymidine掺入后的cpm值反映蛋白或DNA合成。采用t test检验差异的显著性。结果：1、系膜细胞在AngⅡ、PDGF刺激后引起的增殖与肥大，均可被valsartan及benazeprilat抑制。2、比较发现单一用药在同一浓度下，valsartan较benazeprilat能更有效地抑制细胞的增殖与肥大。3、联合用药在同一浓度valsartan benazeprilat均比单用valsartan或benazeprilat效果明显。结论：1、valsartan与benazeprilat均能抑制SHR系膜细胞的增殖与肥大。2、valsartan在抗系膜细胞增殖与肥大作用稍强于benazeprilat。3、在一定浓度条件下联合用药对抗系膜细胞的增殖与肥大作用，较单一用药效果明显。     

骨髓间充质干细胞-支架复合体向软骨诱导分化的实验研究

目的:以骨髓间充质干细胞作为种子细胞,探索组织工程化软骨的构建.方法:分离、获取、扩增骨髓间充质干细胞,通过将扩增的骨髓间充质干细胞接种于聚羟基乙酸(PGA)上,在成软骨诱导因子作用下在体外诱导培养3周后,将实验组和对照组的标本转植入自体兔腹腔内,进行体内培养6～12周后,再进行检测,评估工程化软骨的形成.结果:骨髓间充质干细胞接种于PGA支架上后,经过体外诱导培养和体内培养后,获得标本(7/10)出现软骨组织外观,进行组织学切片可见软骨陷窝,进行Ⅱ型胶原蛋白的免疫组化、Ⅱ型胶原mRNA原位杂交均为阳性.结论:兔骨髓间充质干细胞在成软骨诱导剂作用下,经体外和体内培养后,可生成组织工程化类软骨.     

纤维蛋白胶体外重建兔角膜上皮的实验研究

目的利用组织工程技术体外重建角膜上皮组织,为重建角膜表面提供良好的移植材料和方法。方法以等量凝血酶和纤维蛋白原作用生成的纤维蛋白胶为载体(实验组),种植兔角膜缘组织块,体外培养重建角膜上皮层,每天记录细胞生长覆盖面积,从生长特性、光镜特征、超微结构特点以及免疫细胞化学方面进行观察检测。结果角膜缘上皮细胞在纤维蛋白胶上黏附生长增殖,体外培养7d左右即形成单层上皮细胞,2周左右形成的复层上皮细胞与纤维蛋白胶构成角膜上皮组织经检测与生理状态下的角膜上皮组织相近。实验组与对照组(置盖玻片为载体)比较细胞生长覆盖面积第4天至第7天差异有显著性(P<0.05)。结论以纤维蛋白胶为载体,体外培养的角膜上皮组织片可作为眼表重建角膜上皮移植良好的来源。     

HIGH-LEVEL EXPRESSION OF RATD1A DOPAMINE RECEPTOR cDNA IN MOUSE FIBROBLASTLTK- CELLS BY n-BUTYRATE

1. In orefer to develop a simple, efficient system for the highlvel expression of dopamine recetors in eukaryotic cells, we have studied the effects of n-butyrate on the expression of rat D_1A dopamine receptor cDNA in mouse fibroblast LTK- cells as compared with those of n-butyrate on endogenous D₁ receptor levles in opossum kidney cells.
2. In the transfected LTK- cell mebranes with pRc/CMVD_1A receptor cDNA, a selective D₁ dopamine antagonist, [³H]-SCH 23390, exhibited a K_d of 0.9 ± 0.1 nmol/L and a B_max of 0.35 ± 0.05 pmol/mg protien (n = 5).
3. Addtion of n-butrate (2–10 mmol/L) to the culture medium for 48h dose-dependently increased the D_1A receptor level up to 1.5 ± 0.3 pmol/mg protien (n = 7), although the K_d values were not affected. The increase in receptor level was accompanined by an elevation of selective D₁ agoinist-induced adenyly cyclase activity.
4. In contrast, n-butyrate treatment (2–10 mmol/L) did not affect either endogenous D₁ receptor levels or fendoldopmainduced adenylyl cyclase activity in possum kidney cells.
5. These results sugges n-butyrate is a sueful tool for obtaining high-level expression of D_1A dopamine receptor cDNA in mouse fibroblast LTK- cells.     

Why Are Human Cells Resistant to Malignant Cell Transformation in vitro?1

Transformation of human cells, both induced and spontaneous, is an extremely rare event, whereas rodent cells are relatively easily transformed when treated with a single carcinogenic agent. The present review addresses the question of why human cells are resistant to malignant transformation in vitro. To facilitate understanding of the problem, the process of transformation is divided operationally into two phases, i.e. phase I, immortalization; and phase II, malignant transformation. In human cells, one-phase transformation, i.e., the consecutive occurrence of phases I and II due to the action of a single carcinogenic agent, is observed only rarely. Once human cells are immortalized, however, malignant transformation by chemical carcinogens or oncogenes proceeds, suggesting that for human cells, phase I immortalization is a prerequisite for such transformation to take place. To date, about 20 papers have been published describing protocols for the two-phase transformation of a variety of human epithelial cells and fibroblasts. In most experiments, SV40, human papilloma viruses and their transforming genes are utilized for induction of phase I (immortalization) followed by the use of chemical carcinogens or activated oncogenes for induction of phase II (malignant transformation). Possible mechanisms that would render human cells refractory to transformation are discussed below.     

浆细胞病患者IL-4产生细胞数减少的意义及机制探讨

本文运用APAAP法检测了16名浆细胞患者外周血细胞在PHA刺激下产生IL-4的能力。发现浆细胞病组阳性细胞比率明显低于正常对照组(P<0.001),且阳性细胞比率与患者血清中多克隆IgM、IgA水平呈正相关(r=0.806和r=0.703)。在正常人外周血中加入CRP50mg/L,经PHA刺激后IL-4产生细胞也明显减少。作者假设,由于IL-6增高引起CRP等急性期相蛋白大量分泌,使IL-4产生受到明显抑制,从而使B细胞激活发生障碍是浆细胞病中多克隆免疫球蛋白合成抑制的主要原因。     

苏乐康等抑制细胞转化能力及其机制的探讨

研究了苏乐康、绿茶提取物对~(60)钴γ射线和雌性激素联合诱发叙利亚金黄地鼠胚胎细胞恶性转化的抑制能力,并用脉冲辐解技术,对其抑制机制进行初步探讨。实验结果表明,苏乐康、绿茶提取物对γ射线和雌性激素联合诱发的金黄地鼠胚胎细胞恶性转化的抑制率分别为70.15％(P<0.05)和81.59％(P<0.05),它们的这种抑制能力与其清除超氧阴离子的能力有关,     

细小病毒H－1对正常仓鼠肝细胞DNA周期动力学的影响

健康成年金黄仓鼠腹腔内接种ＰＶＨ－１（５×１０６ｐｆｕ），ＦＣＭ动态检测肝细胞ＤＮＡ周期动力学变化，结果显示：ＰＶＨ－１接种后处于Ｇ０＋Ｇ１期的肝细胞与对照组动物相比无显著差异。Ｓ期肝细胞在第３天显著高于对照组动物（Ｐ＜０．０５），且在第７天时仍呈上升趋势，第１４天到３０天趋于正常水平。Ｇ２＋Ｍ期肝细胞在ＰＶＨ－１接种后第３０天升高（Ｐ＜０．０５）。结果提示，动物在ＰＶＨ－１接种后第３到第７天是病毒在肝细胞中的复制高峰，并阻滞仓鼠处于Ｓ期肝细胞分裂进入Ｇ２＋Ｍ期，但是这种阻滞作用较短暂、并可逆，在ＰＶＨ－１接种后１４～３０天自然消失。     

An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases

To examine the excretion of urinary epidermal growth factor (EGF) in urological diseases and the relationship of EGF urine levels with transitional cell carcinoma (TCC), we measured the concentration of EGF by radioimmunoassay. The series comprised patients with active TCC (n=50), others in tumor-free status (n=29) and with non-neoplastic inflammatory diseases (n=43), and normal controls (n=50). Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P<0.005). Mean EGF levels of patients who had previous bladder tumor resection (n=21) were not statistically different from normal controls (P=0.2). For patients with active TCC, EGF urine levels showed a significant inverse relationship to increasing tumor grade (P=0.02). In addition, subjects who had received nephrectomy for pelvic carcinoma (n=8) showed significantly lower mean EGF values than those with intact kidneys (n=21), irrespective of sex (P<0.05). Immunostaining of EGF on non-neoplastic kidney (n=9) revealed reactivity in the distal convoluted tubules and thick ascending limbs of Henle. Our results suggest that the kidney is the major source of urinary EGF. Its excretion in urine is decreased in both inflammatory and neoplastic diseases of the urinary tract. EGF may play an important part in the biological activity of TCC. Further study is indicated to investigate the monitoring of EGF urine levels as a marker of recurrence for EGF receptor-positive TCC.